Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
73
Stocks News & Analysis
stocks
Shorts circle BHP ahead of listing unification: ASX’s most shorted stocks
stocks
Mayne Pharma woes to persist for 2020
stocks
CSL remains favourite, but biotech field broadening
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,126.90 | 73.70 | 0.92% |
CAC 40 | 7,876.36 | 85.65 | 1.10% |
DAX 40 | 22,539.98 | 376.49 | 1.70% |
Dow JONES (US) | 42,007.73 | 5.97 | 0.01% |
FTSE 100 | 8,634.80 | 51.99 | 0.61% |
HKSE | 23,206.84 | 87.26 | 0.38% |
NASDAQ | 17,435.64 | 136.36 | 0.79% |
Nikkei 225 | 35,624.48 | 6.92 | 0.02% |
NZX 50 Index | 12,312.60 | 42.60 | 0.35% |
S&P 500 | 5,629.91 | 18.06 | 0.32% |
S&P/ASX 200 | 7,925.20 | 81.80 | 1.04% |
SSE Composite Index | 3,348.44 | 12.69 | 0.38% |